DLL4 Binding Proteins Targeting Tumor Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for therapeutic agents that can effectively target the DLL4-Notch pathway to inhibit or prevent tumor angiogenesis and growth, as existing methods like small molecule inhibitors are toxic and non-specific, suppressing normal tissue expression of the Notch receptor.
Innovation Solution
Development of DLL4 binding proteins, including rat monoclonal antibodies and their derivatives, that bind human DLL4 with high affinity, capable of neutralizing its activity to specifically inhibit tumor angiogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors of the Notch receptor are used, then inhibition of the Notch-signaling pathway is achieved, but toxicity increases due to suppression of wild type tissue expression of Notch receptors throughout the body
Solution Approach 1:
The patent applies local quality by designing antibodies that specifically target DLL4 expressed in tumor blood vessels while sparing normal tissue. The antibodies bind to DLL4 with high affinity and neutralize its activity locally at the tumor site, preventing systemic suppression of Notch receptors in wild type tissues. This localized action resolves the contradiction between achieving pathway inhibition and avoiding toxicity to normal tissues.
2Reliability
If DLL4 binding proteins are developed to specifically target tumor angiogenesis, then anti-tumor activity is enhanced, but device complexity increases compared to small molecule inhibitors
Solution Approach 1:
The patent employs copying by using antibody variable regions (Fab fragments) that replicate the binding specificity of full-length antibodies against DLL4. These simplified copies retain the high affinity and neutralizing activity needed for anti-tumor effect while being less complex than whole antibodies. This approach balances enhanced anti-tumor activity with reduced structural complexity compared to using complete monoclonal antibodies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The DLL4 binding proteins effectively inhibit tumor angiogenesis by targeting the DLL4-Notch pathway, potentially offering a safer and more specific approach than traditional small molecule inhibitors, with enhanced anti-tumor activity even against resistant tumors.
Implementation Method 1
proteins that bind human DLL4... capable of binding human DLL4 with high affinity... capable of neutralizing human DLL4
Data Source
AI summary
DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.